Evidence map›Paper›PMID 42860490›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Clinical and serological outcomes of syphilis: an 18-year retrospective cohort study on predictors of treatment response and seroreversion in Türkiye.

Hatice Sertkaya, Esra Kazak, Ayşe Melda Payaslıoğlu, Uğur Önal, Yasemin Heper, Emel Yılmaz, Emin Halis Akalın

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hatice SertkayaDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.ORCID http://orcid.org/0000-0002-2258-046X
Esra KazakDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye. eskazak@uludag.edu.tr.ORCID http://orcid.org/0000-0002-7380-2501
Ayşe Melda PayaslıoğluDepartment of Medical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.ORCID http://orcid.org/0009-0004-1725-0644
Uğur ÖnalDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.ORCID http://orcid.org/0000-0001-6194-3254
Yasemin HeperDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.ORCID http://orcid.org/0000-0002-6635-5416
Emel YılmazDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.ORCID http://orcid.org/0000-0002-3894-1231
Emin Halis AkalınDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.ORCID http://orcid.org/0000-0001-7530-1279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite established protocols, the global resurgence of syphilis remains a public health challenge, with outcomes influenced by disease stage and host factors. This study described 18-year epidemiological trends and identified predictors of serological treatment response and long-term seroreversion.

methodsWe retrospectively analyzed 503 adults diagnosed with syphilis between 2005 and 2022 and classified disease stages according to CDC criteria. Treatment response was defined as a ≥ 4-fold decline in rapid plasma reagin (RPR) titers within 12 months for early-stage and 24 months for late-stage syphilis, while seroreversion was defined as a non-reactive RPR. Overall, 157 patients were included in the treatment-response analysis and 159 in the seroreversion analysis, the latter including two additional patients who achieved seroreversion before treatment-response assessment. Independent predictors were identified using multivariable logistic regression.

resultsSyphilis cases increased significantly after 2015, with late-stage disease accounting for 75.7% (n = 381) of diagnoses. Early syphilis rose from 10.5% (2005-2015) to 30.2% after 2015 (p < 0.001). Among patients with available HIV test results, 29.4% (134/456) of cases were in people with HIV. Early-stage syphilis was more frequent in people living with HIV (PLWH) than in HIV-negative individuals (32% vs. 20.1%). Among patients with follow-up, 75.2% (118/157) achieved a serological response. In multivariate analysis, late-stage syphilis was a negative predictor of response (OR 0.22, 95% CI 0.07-0.76; p = 0.016), while baseline RPR titers ≥ 1:8 were a strong positive predictor (OR 8.18, 95% CI 1.72-38.85; p = 0.008). HIV status was not independently associated with response (p > 0.05). Seroreversion occurred in 35.8%, with no independent predictors identified.

conclusionsThe syphilis burden has grown, driven by delayed diagnosis and late-stage predominance despite recent trends toward earlier detection. In this cohort, disease stage and baseline RPR titers were stronger predictors of serological response than HIV status. The higher frequency of early-stage diagnosis in PLWH is consistent with the potential impact of intensified screening and may reflect differences in healthcare engagement and testing practices compared with the general population.

Indexed as

HIV co-infectionRapid plasma reagin (RPR)SeroreversionSyphilisTreatment responseTreponema pallidum

Identifiers

PMID42860490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.